Get started

Financials · KRRO

Korro Bio Inc. (KRRO) financials

For the twelve months ended Sep 30, 2026, Korro Bio Inc. reported $1.29M of revenue and -$106.13M of net income.

Revenue, TTM
$1.29M
Revenue growth, YoY
-82.5%
Net income, TTM
-$106.13M
Net margin
-8214.5%
Free cash flow, TTM
-$63.87M
EPS, diluted, TTM
-$9.07
Cash
$40.22M
P/S
158.93
Market cap
$205.3M
Annual revenue$6.39M
FY2019FY2025
Annual net income-$117.26M
FY2017FY2025
Annual free cash flow-$79.08M
FY2017FY2025

KRRO revenue and earnings growth

KRRO revenueQ3 2026$0

Quarter YoY
-100.0%
FY YoY
+181.5%
5Y CAGR
-29.6%

KRRO revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), down 100.0% from a year earlier. For the full fiscal 2025 it was $6.39M, up 181.5% from fiscal 2024. Compound annual growth was -29.6% over 5 years.

KRRO net incomeQ3 2026-$17.55M

KRRO net income was -$17.55M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$18.06M a year earlier. For the full fiscal 2025 it was -$117.26M, compared with -$83.58M in fiscal 2024.

KRRO EPSQ3 2026-$0.98

KRRO diluted EPS was -$0.98 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$12.48, compared with -$9.37 in fiscal 2024.

KRRO free cash flowQ3 2026-$12.96M

KRRO free cash flow was -$12.96M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$17.35M a year earlier. For the full fiscal 2025 it was -$79.08M, compared with -$77.98M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$6.39M$2.27M$0$0$14.07M$36.98M$28.95M--
Research and development$65.58M$63.64M$57.25M$42.20M$60.92M$37.41M$18.78M$11.88M$11.97M
Selling, general and admin$28.16M$30.55M$27.28M$16.80M$37.18M$27.12M$14.84M$7.06M$4.34M
Operating income-$121.86M-$91.91M-$84.53M-$59.00M-$84.03M-$27.55M-$20.68M-$18.94M-$16.31M
Interest expense---$961.0K$764.0K$0---
Pre-tax income-$116.62M-$83.44M-$81.14M-$58.02M-$84.67M-$26.48M-$18.75M--
Income tax$637.0K$141.0K$27.0K$10.0K$15.0K$35.0K$0--
Net income-$117.26M-$83.58M-$81.17M-$58.03M-$84.69M-$26.51M-$18.75M-$19.17M-$20.24M
EPS, basic-$12.48-$9.37-$53.08-$227.42-$2.47-$0.82-$2.29-$12.53-$28.79
EPS, diluted-$12.48-$9.37-$53.08-$227.42-$2.47-$0.82-$2.29-$12.53-$28.79
Diluted shares9.4M8.9M1.5M255,17534.4M32.3M8.6M1.5M702,918

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$21.82M$55.64M$166.15M$36.33M$79.64M$220.34M$200.16M$42.19M-
Short-term investments$53.33M$70.45M$0$18.91M-----
Current assets$82.37M$131.53M$172.73M$57.08M$134.75M$225.06M$221.35M$42.94M-
Total assets$113.51M$226.24M$221.66M$73.74M$185.36M$264.72M$223.22M$44.55M-
Current liabilities$11.94M$14.96M$19.48M$8.70M$11.43M$26.63M$52.78M$3.77M-
Short-term debt---$10.00M$833.0K----
Long-term debt------$180.0K$349.0K-
Total debt------$180.0K$349.0K-
Total liabilities$62.07M$65.83M$51.75M$8.91M$54.53M$72.23M$55.86M$4.12M-
Shareholders' equity$51.44M$160.41M$169.91M-$99.03M-$42.21M$192.49M$167.36M-$48.28M-$29.64M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$78.56M-$60.07M-$67.28M-$53.65M-$76.06M-$45.19M$34.22M-$17.02M-$14.61M
Capital expenditures$518.0K$17.90M$7.84M$5.14M$2.91M$6.67M$1.06M$436.0K$1.86M
Free cash flow-$79.08M-$77.98M-$75.12M-$58.78M-$78.97M-$51.86M$33.15M-$17.46M-$16.48M
Investing cash flow$43.99M-$123.35M$11.16M$11.06M-$66.13M$10.40M-$18.26M-$436.0K-$1.86M
Financing cash flow$685.0K$69.36M$187.76M$18.0K$1.36M$56.69M$142.01M$41.71M$27.98M
Stock-based compensation---$19.83M$21.75M$9.98M$3.61M$455.0K$91.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY181.5%---100.0%-62.0%27.8%---
Operating margin-1906.4%-4047.1%---597.3%-74.5%-71.4%--
Net margin-1834.5%-3680.4%---602.0%-71.7%-64.8%--
Free cash flow margin-1237.2%-3433.6%---561.4%-140.2%114.5%--
Return on equity-228.0%-52.1%-47.8%---13.8%-11.2%--
Return on assets-103.3%-36.9%-36.6%-78.7%-45.7%-10.0%-8.4%-43.0%-
Current ratio6.908.798.876.5611.798.454.1911.38-
Debt to equity------0.00--

Source: XBRL data Korro Bio Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

KRRO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
KRRO$1.29M-82.5%-$106.13M-8214.5%$205.3M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

KRRO FAQ

8 questions
  • What is KRRO revenue?
    Korro Bio Inc. (KRRO) reported $1.29M of revenue for the twelve months ended Sep 30, 2026. That is down 82.5% from the year before. Revenue for fiscal 2025 was $6.39M.
  • Is KRRO profitable?
    No. Korro Bio Inc. reported a net loss of $106.13M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does KRRO have?
    Korro Bio Inc. reported $40.22M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is KRRO revenue growing?
    Korro Bio Inc.'s revenue changed +181.5% in fiscal 2025, to $6.39M. Its compound annual growth rate was -29.6% over 5 years.
  • What is KRRO free cash flow?
    Korro Bio Inc. generated -$63.87M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$63.70M less capital expenditures.
  • What is KRRO earnings per share?
    Diluted earnings per share were -$9.07 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did KRRO last report financial results?
    The latest statements here come from Korro Bio Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this KRRO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Korro Bio Inc. files with the SEC. It is provided for information only and is not investment advice.